Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Liabilities and Shareholders Equity (2020 - 2025)

SAB Biotherapeutics (SABS) has disclosed Liabilities and Shareholders Equity for 6 consecutive years, with $172.8 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Liabilities and Shareholders Equity rose 291.01% year-over-year to $172.8 million, compared with a TTM value of $424.5 million through Dec 2025, up 83.57%, and an annual FY2025 reading of $172.8 million, up 291.01% over the prior year.
  • Liabilities and Shareholders Equity was $172.8 million for Q4 2025 at SAB Biotherapeutics, down from $183.4 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $183.4 million in Q3 2025 and bottomed at $28.3 million in Q3 2023.
  • Average Liabilities and Shareholders Equity over 5 years is $75.5 million, with a median of $60.7 million recorded in 2022.
  • The sharpest move saw Liabilities and Shareholders Equity plummeted 55.09% in 2022, then soared 291.01% in 2025.
  • Year by year, Liabilities and Shareholders Equity stood at $81.1 million in 2021, then tumbled by 37.26% to $50.9 million in 2022, then skyrocketed by 64.9% to $83.9 million in 2023, then tumbled by 47.35% to $44.2 million in 2024, then skyrocketed by 291.01% to $172.8 million in 2025.
  • Business Quant data shows Liabilities and Shareholders Equity for SABS at $172.8 million in Q4 2025, $183.4 million in Q3 2025, and $30.1 million in Q2 2025.